A detailed history of Wells Fargo & Company transactions in Regenxbio Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 34,844 shares of RGNX stock, worth $305,233. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,844
Previous 29,635 17.58%
Holding current value
$305,233
Previous $624,000 34.78%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$11.51 - $21.53 $59,955 - $112,149
5,209 Added 17.58%
34,844 $407,000
Q1 2024

May 10, 2024

BUY
$12.17 - $24.61 $47,377 - $95,806
3,893 Added 15.12%
29,635 $624,000
Q4 2023

Feb 09, 2024

SELL
$12.89 - $20.82 $134,868 - $217,839
-10,463 Reduced 28.9%
25,742 $462,000
Q3 2023

Nov 13, 2023

SELL
$16.46 - $19.99 $162,015 - $196,761
-9,843 Reduced 21.38%
36,205 $595,000
Q2 2023

Aug 15, 2023

BUY
$17.23 - $21.71 $5,565 - $7,012
323 Added 0.71%
46,048 $920,000
Q1 2023

May 12, 2023

BUY
$18.08 - $24.55 $513,905 - $697,809
28,424 Added 164.29%
45,725 $864,000
Q4 2022

Feb 13, 2023

SELL
$20.4 - $24.73 $159,874 - $193,809
-7,837 Reduced 31.18%
17,301 $392,000
Q3 2022

Nov 14, 2022

SELL
$22.29 - $35.04 $13,351 - $20,988
-599 Reduced 2.33%
25,138 $665,000
Q2 2022

Aug 12, 2022

SELL
$19.35 - $35.04 $370,339 - $670,630
-19,139 Reduced 42.65%
25,737 $636,000
Q1 2022

May 16, 2022

SELL
$24.62 - $34.31 $804,360 - $1.12 Million
-32,671 Reduced 42.13%
44,876 $1.49 Million
Q4 2021

Feb 14, 2022

SELL
$30.19 - $40.28 $25,329 - $33,794
-839 Reduced 1.07%
77,547 $2.54 Million
Q3 2021

Nov 15, 2021

BUY
$29.09 - $45.68 $48,027 - $75,417
1,651 Added 2.15%
78,386 $3.29 Million
Q2 2021

Aug 16, 2021

BUY
$32.46 - $40.48 $192,552 - $240,127
5,932 Added 8.38%
76,735 $2.98 Million
Q1 2021

May 13, 2021

BUY
$33.61 - $49.95 $956,305 - $1.42 Million
28,453 Added 67.19%
70,803 $2.42 Million
Q4 2020

Feb 09, 2021

BUY
$26.52 - $49.35 $190,970 - $355,369
7,201 Added 20.49%
42,350 $1.92 Million
Q3 2020

Nov 05, 2020

SELL
$27.01 - $40.26 $217,025 - $323,489
-8,035 Reduced 18.61%
35,149 $967,000
Q2 2020

Aug 13, 2020

BUY
$27.75 - $43.44 $28,804 - $45,090
1,038 Added 2.46%
43,184 $1.59 Million
Q1 2020

May 14, 2020

BUY
$21.5 - $54.2 $906,139 - $2.28 Million
42,146 New
42,146 $1.37 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $379M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.